RecruitingNCT06274788
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
Studying Parenteral nutrition-associated cholestasis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fresenius Kabi
- Intervention
- Omegaven® (fish oil triglycerides) Injectable Emulsion(drug)
- Enrollment
- 40 target
- Eligibility
- 17 years · All sexes
- Timeline
- 2024 – 2027
Study locations (10)
- Memorial Health Service, Fountain Valley, California, United States
- University of California Los Angeles, Los Angeles, California, United States
- The University of Chicago, Chicago, Illinois, United States
- Children's Hospital Corporation d/b/a Boston Children's Hospital, Boston, Massachusetts, United States
- Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Board of Regents of the University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Baylor College of Medicine Houston, Houston, Texas, United States
- The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
- Seattle Children's Hospital d/b/a Seattle Children's Research Institute, Seattle, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06274788 on ClinicalTrials.govOther trials for Parenteral nutrition-associated cholestasis
Additional recruiting or active studies for the same condition.
See all trials for Parenteral nutrition-associated cholestasis →